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S U M M A R Y
Objectives: The purpose of this study was to undertake an epidemiological analysis of an increase in
Bordetella pertussis activity during the period January 1 to August 31, 2012 in Alberta, Canada. B. pertussis
testing was done using an IS481 real-time PCR assay with PCR-positive and indeterminate specimens
cultured and stored for further analysis.
Methods: Laboratory data were linked to Alberta Health (AH) cases that were reported in the
Communicable Disease Reporting System (CDRS) to identify case isolates; exclusion criteria were used
to avoid biases. Case isolates were analyzed at the National Microbiology Laboratory (NML) by pulsed-ﬁeld
gel electrophoresis (PFGE) and multilocus sequence typing (MLST). Pertussis immunization data were
extracted from the Alberta Provincial Immunization Repository (Imm/ARI) and linked to the pertussis cases.
Results: Using PFGE and MLST, 52 case isolates could be divided into two main sequence type groups:
41 cases belonged to the ST-1 group (ST-1 and the novel ST-19) and 11 cases belonged to the ST-2 group (ST-
2 and the novel ST-20). Of the total cases genotyped (N = 52), 18 (34.6%) had a history of immunization, 28
(53.8%) were not immunized, and six (11.6%) had an unknown immunization history. Of the total non-
immunized cases, 25/28 (89.2%) belonged to the ST-1 group. Furthermore, of the 41 ST-1 group cases,
25 were not immunized compared to only three of the ST-2 group cases (p = 0.0004, Fisher’s exact test).
Conclusions: This study shows the dominance of two genotypes of B. pertussis in our jurisdiction and
indicates less pertussis immunization in individuals infected with the ST-1 group.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).
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In the spring of 2012, there was an increase in the incidence of
pertussis in Alberta, Canada (population 3.8 million, 2012), which
rapidly became a concern to public health practitioners. Also of
concern was a signiﬁcant increase in the incidence in children aged
<5 years. The previous 5-year average for the same time period
was 89.4 cases, and in the South and Edmonton zones the number
of cases was 3 and 5 times as high, respectively.1 Various causes for
this increase were postulated, including non-vaccination, waning* Corresponding author. Tel.: +1 780 407 3068; fax: +1 780 407 8961.
E-mail address: steven.drews@albertahealthservices.ca (S.J. Drews).
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).immunity, the relatively high sensitivity of Bordetella pertussis
molecular testing platforms, and potential primary vaccine failure.
Although vaccination status and molecular typing of isolates has
been discussed in prior studies, little has been done to directly link
vaccine status to genotype. The objective of this study was to
describe the predominant genotype strains of B. pertussis-positive
cases in the winter, spring, and summer of 2012 in Alberta, Canada,
and to link genotype to vaccination status.
2. Methods
The Provincial Laboratory of Public Health (ProvLab) undertook
an IS481 PCR for B. pertussis detection from respiratory specimens
as per routine, followed by culture conﬁrmation of PCR-positiveciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
K. Simmonds et al. / International Journal of Infectious Diseases 29 (2014) 223–225224specimens, as described previously.1,2 The selection of B. pertussis
isolates for genotyping was as follows. Viable B. pertussis-positive
culture isolates and cases were ﬁrst linked and then isolates from
known household contacts of ﬁrst cases were excluded. As part of
the non-routine public health investigation, culture-conﬁrmed
case isolates were analyzed at the National Microbiology
Laboratory (NML) by pulsed-ﬁeld gel electrophoresis (PFGE) and
genotyping.3 A multilocus sequence typing (MLST) approach was
carried out using the ﬁve gene targets of ptxS1, prn, ﬁm3, fhaB, and
ptxP.3
Alberta uses the Public Health Agency of Canada case
deﬁnition of pertussis.1 Laboratory data were linked to an Alberta
Health (AH) case dataset to identify pertussis cases as reported in
the automated provincial Communicable Disease Reporting
System (CDRS). Immunization status was also linked to case
data using CDRS.4 SAS 9.2 (SAS Institute Inc., Cary, NC, USA) was
used for all data manipulation and analyses. p-Values of 0.05
were considered signiﬁcant. BioNumerics 5.10 (Applied Maths,
Austin, TX) was used to create dendrograms for comparison of
PFGE patterns.
3. Results
There were 217 cases in total, with 142 laboratory conﬁrmed
cases and 75 not laboratory conﬁrmed. For genotyping, exclusion
criteria included known household contacts of cases (n = 39), cases
without clinical isolates (n = 75), and cases without viable isolates
(n = 51). There were 52 isolates from cases submitted to the NML
for genotyping. Pertussis cases selected for genotyping were
similar to cases not typed with regard to factors such as gender (28/
52, 54% male), median age (6 years), completion of immunization
status (11/52, 21% complete for age), and association with
outbreaks (10/52, 19%). Cases linked to typed isolates were more
likely to be <1 year of age (16/52, 30.8%) than cases where no B.
pertussis genotyping was done (14/185, 8.5%; p = 0.0003). Cases






Figure 1. Dendrogram created in BioNumerics using XbaI and SpeI restricted D21.2%) than cases where no B. pertussis genotyping was done (12/
165, 7.3%; p = 0.014).
Standardized NML PFGE proﬁles are noted in Figure 1; AB alpha
descriptors were given to each apparent strain. The percentage
relatedness or similarities were calculated based on analysis of
these isolates; as the number of strains to be analyzed increases,
the percentage relatedness of strains may change, as described
previously.3 There were ﬁve different cluster patterns, and
16 different proﬁles were detected in which four proﬁles (proﬁles
A, A1, A3, and F) were represented by more than one isolate.
Proﬁles A1 to A7 were either closely related or possibly related to
proﬁle A. Proﬁles B, C, D, and E, belonging to a second cluster, were
closely related and different from the third cluster with designated
patterns F and G. The remaining two proﬁles, H and I, are
independent from each other. All the proﬁles within the cluster are
closely related to each other, but they are different from the rest of
the other cluster proﬁles (Figure 1).
MLST results are available in Table 1. Combining MLST and PFGE
data produced the following ﬁndings. Isolates with ST-1 and ST-19
MLST proﬁles linked to PFGE proﬁles A and A1–A7 (Figure 1).
Isolates with ST-2 and ST-20 proﬁles linked to PFGE proﬁles B–I.
For later epidemiological analysis, these ST-2 and ST-20 isolates
were combined as ST-2 group. Novel genotypes were identiﬁed: a
single isolate with a proﬁle A1 as prn18 (GenBank accession
number KJ433480), and a single isolate with a proﬁle A1 as ptxP20
(GenBank accession number KJ433481).
B. pertussis vaccination histories of all cases, laboratory
conﬁrmed cases, and cases linked to PFGE are shown in
Table 2. Of the 52 pertussis cases genotyped, 11 (21%) had a
complete series of pertussis immunizations, seven (13%) had a
partial series of pertussis immunizations, 28 (54%) had a deﬁnitive
history of no pertussis immunizations, and six (12%) could not
remember an immunization history to pertussis and the immuni-
zation repository had no records, or they were lost to follow-up. Of
the 41 ST-1 cases, 25 had a deﬁnitive history of no pertussis
immunizations compared to only three of the ST-2 cases












































































NA from 52 Bordetella pertussis strains isolated in Alberta, Canada in 2012.
Table 1
MLST types of Bordetella pertussis and speciﬁc loci descriptors
STa Number of strains ptxS1 prn ﬁm3 fhaB ptxP
1 40 ptxS1A prn2 ﬁm3B fhaB1 ptxP3
2 10 ptxS1A prn2 ﬁm3A fhaB1 ptxP3
19 1 ptxS1A prn18 ﬁm3B fhaB1 ptxP3
20 1 ptxS1A prn2 ﬁm3A fhaB1 ptxP20
MLST, multilocus sequence typing.
a For later epidemiological analysis, ST-1 and ST-19 were deﬁned as ST-1 group,
and ST-2 and ST-20 as ST-2 group.
Table 2
Differences in immunization history between all cases, laboratory conﬁrmed cases,





Completely immunized 53 (24%) 39 (27%) 11 (21%)
Partially immunized 31 (14%) 23 (16%) 7 (13%)
Not immunized 108 (50%) 65 (46%) 28 (54%)
Unknown 25 (12%) 15 (11%) 6 (12%)
Total 217 142 52
K. Simmonds et al. / International Journal of Infectious Diseases 29 (2014) 223–225 2254. Discussion
The dominance of ST-1 group and ST-2 group MLST patterns of
B. pertussis is similar to the patterns seen in Ontario, Canada,3 with
alleles similar to those seen recently in Washington State, USA.5 B.
pertussis genotype data should be interpreted in light of changes in
vaccination strategies over the last 20 years in Alberta, which may
have impacted vaccine coverage and efﬁcacy, as well as circulating
genotypes.6–8 There have been several changes in pertussis
vaccination in Alberta. 1n 1997, acellular pertussis vaccine
replaced whole-cell vaccine, which had been used in Alberta since
1939. In September 2004, Adacel, a combined diphtheria, tetanus,
and acellular pertussis vaccine, replaced a tetanus/diphtheria
booster for grade 9 students for added protection. Furthermore, the
infant formulation used for children aged 2 months to 7 years
contains higher concentrations of B. pertussis antigens than the
adult/adolescent vaccine.1 As changes in vaccine composition have
been postulated to impact on genotype, the genotyping in this
study should be considered to be a snapshot of what was present in
Alberta for a speciﬁc time period.6Poor vaccine coverage in pertussis cases has been described
previously in our region.1 Although non-vaccination status was
more likely to be associated with ST-1 group isolates and less with
ST-2 group, the authors caution against over-interpretation of this
point due to some potential biases, including biases in selection of
isolates for typing from hospitalized patients and patients <1 year
of age. In the future, analysis of trends in separate speciﬁc
populations such as pediatric or hospitalized/community patients,
or by degree of illness, may also provide a less biased analysis of the
impact of variables on B. pertussis infection.9
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